Multimodality Treatment of Locally Advanced Pancreatic Cancer

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 1994 Jan 1

PMID 8204534

Citations 4

Authors

D J Wagener

P H de Mulder

J A Wils

Affiliations

Soon will be listed here.

Abstract

Background: The prognosis of locally advanced pancreatic cancer is poor (median survival 3-5 months). In view of the localized character of this disease several groups have explored the value of combined modality treatment. The conditions are that a good local treatment and an effective systemic treatment are available.

Patients And Methods: The results of irradiation and of chemotherapy in advanced disease are reviewed.

Results: An overview of combined modality treatment has been given.

Conclusions: Results of combined modality treatment are superior to irradiation alone or to symptomatic treatment.

Citing Articles

Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway.

Fei Q, Jin K, Shi S, Li T, Guo D, Lin M Acta Biochim Biophys Sin (Shanghai). 2024; 56(4):513-524.

PMID: 38229544 PMC: 11094629. DOI: 10.3724/abbs.2023286.

Neoadjuvant, adjuvant, and palliative treatment of pancreatic cancer.

Birk D, Beger H Curr Gastroenterol Rep. 2001; 3(2):129-35.

PMID: 11276380 DOI: 10.1007/s11894-001-0009-4.

Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.

Prott F, Schonekaes K, Preusser P, Ostkamp K, Wagner W, Micke O Br J Cancer. 1997; 75(4):597-601.

PMID: 9052417 PMC: 2063297. DOI: 10.1038/bjc.1997.104.

Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature.

Fazeny B, Baur M, Prohaska M, Hudec M, Kremnitzer M, Meryn S J Cancer Res Clin Oncol. 1997; 123(1):45-52.

PMID: 8996540 DOI: 10.1007/BF01212614.